
- Volume 0 0
ADVISORY COMMITTEE WILL ADDRESS RISK COMMUNICATION
The FDA will form a new advisory committee of outside specialists to advise the agency on how to inform the public about the risks and benefits of medicines and medical devices. The Risk Communication Advisory Committee will:
- Help the FDA better understand the communication needs and priorities of the general public
- Advise the FDA on the development of strategic plans to communicate product risks and benefits
- Make recommendations to the FDA based on current research about crafting risk and benefit messages, as well as how to effectively communicate specific product information to vulnerable audiences
The committee "will bring together a broad range of experts and views to help improve the FDA's communication of the science-based information about product risks and benefits that the public needs to make informed decisions."
Articles in this issue
about 18 years ago
The Facts of Liceabout 18 years ago
compounding HOTLINEabout 18 years ago
can you READ these Rxs?about 18 years ago
can you READ these Rxs?about 18 years ago
WARFARIN-RELATED COMPLICATIONS INCREASE WITH AGEabout 18 years ago
IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?about 18 years ago
HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMESabout 18 years ago
LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERSabout 18 years ago
Embracing and Advocating Change in the Pharmacy Professionabout 18 years ago
Improving Pharmaceutical Care of the Elderly Patient with GERDNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.